UBS Upgrades Aegon Stock Outlook
Recently, UBS has shown confidence in Aegon (NYSE: AEG) NV by upgrading its stock rating from Neutral to Buy. The firm has established a new price target of EUR 6.55, slightly below the previous target of EUR 6.65. This change in rating reflects UBS's optimistic view on Aegon's potential growth.
Future Share Buybacks and Earnings Yield
UBS anticipates that Aegon will continue its strategy of share buybacks, projecting an annual repurchase of approximately EUR 300 million starting in 2025. This implies a significant earnings yield of 9% for fiscal year 2025, outpacing the average in the sector while aligning with the performance of other Dutch insurance firms.
Potential Special Buyback Announcement
Moreover, UBS sees the possibility for Aegon to announce a special share buyback of around EUR 100 million, representing approximately 1% of the company's market capitalization. This announcement is expected during the presentation of third-quarter results on November 15, where it is believed that Aegon will have concluded its current EUR 200 million share repurchase program.
Financial Forecast and Strategic Adjustments
UBS analysts have also examined the potential of Aegon divesting its stake in ASR, another insurer. However, the report indicates that such a sale may not significantly add to shareholder value. The firm trusts Aegon to mitigate risks in its non-core U.S. investments, which could further improve the company's financial standing and stock performance.
Positive Financial Results Post-Mortality Risks
Aegon has recently been in the spotlight following an optimistic revision of its full-year 2024 operating profit forecast, now expecting between EUR 800 million and EUR 900 million, increasing from the previous estimate of EUR 700 million to EUR 800 million. Despite some challenges surrounding mortality risk, Berenberg has also maintained its Buy rating on Aegon, demonstrating confidence in the company amidst earnings fluctuations.
Strategic Reserves Mitigation
In response to rising mortality costs, Aegon has taken measures to bolster reserves, allocating an additional USD 400 million specifically for anticipated U.S. mortality risks. This proactive strategy is aimed at decreasing mortality costs by USD 50 million bi-annually under the International Financial Reporting Standards (IFRS) operating profit guidelines.
Mixed Financial Response
During its earnings call, Aegon reported a mixed financial picture, noting an 8% decline in operating results compared to the previous year due to unfavorable mortality claims in the U.S. However, the company's solvency ratios displayed improvements, maintaining alignment with their financial targets for 2025.
InvestingPro Insights on Aegon NV
Insights from recent data indicate that Aegon NV has a market capitalization of $10.32 billion, with a strong dividend yield of 4.73%. This attractive yield is supplemented by Aegon's impressive dividend growth of 37.55% over the last year, underscoring the firm’s commitment to shareholder returns.
Commitment to Shareholder Returns
Aegon has aggressively pursued share buybacks and has successfully raised its dividend for four consecutive years, fostering investor confidence in continued repurchases and the possibility of special buybacks, which UBS anticipates.
Return to Profitability on the Horizon
Even though Aegon reported a negative operating income of $249.6 million over the last year, analysts are optimistic about the company's prospects of returning to profitability this year. This confidence is mirrored in Aegon's stock performance, with a commendable total return of 43.46% over the past twelve months.
Frequently Asked Questions
What is UBS's new rating for Aegon stock?
UBS upgraded Aegon stock from Neutral to Buy.
What is Aegon's projected earnings yield for FY25?
The projected earnings yield for Aegon in FY25 is 9%.
Is there a potential special buyback for Aegon planned?
Yes, a special buyback of around EUR 100 million is expected to be announced on November 15 during the Q3 results presentation.
What are Aegon's recent financial forecasts?
Aegon forecasts an operating profit of EUR 800 million to EUR 900 million for the full-year 2024, revised upwards.
How has Aegon responded to mortality cost increases?
Aegon has allocated an additional USD 400 million for future U.S. mortality risks to bolster its reserves.
